Gero announced that it has entered into a research collaboration with Pfizer to apply Gero's machine learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale human-based data. As part of this research collaboration, the companies will leverage Pfizer's expertise and Gero's technology platform with the aim to identify genes and pathways linked to fibrotic diseases. Pfizer may advance the potential therapeutic targets and would be responsible for further preclinical and clinical development.

Gero will receive an upfront payment and is eligible to receive discovery milestone payments if the project progresses.